Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
NCT00267501 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000
Last updated 2025-09-17
Summary
The purpose of this study is to elucidate the mechanisms underlying eosinophil growth, survival, migration, and function and to investigate and further characterize the pathophysiology of, clinical manifestations of, and spectrum of disease severity of eosinophilic inflammation in humans.
Conditions
- Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease
- Food Allergy
Sponsors & Collaborators
-
Children's Hospital Medical Center, Cincinnati
lead OTHER
Principal Investigators
-
Marc E. Rothenberg, M.D., Ph.D. · Cincinnati Children's Hospital Medical Center
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-05-31
- Primary Completion
- 2050-01-31
- Completion
- 2050-01-31
Countries
- United States
Study Locations
More Related Trials
-
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
NCT00635089 ·Status: COMPLETED ·Phase: PHASE3
-
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
NCT00017862 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
EoE Food Test Pilot Study
NCT07023380 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis
NCT02908360 ·Status: COMPLETED
-
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
NCT05175352 ·Status: COMPLETED ·Phase: PHASE1
-
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
NCT06477653 ·Status: RECRUITING ·Phase: PHASE2
-
Dupilumab Therapy for EGIDs
NCT07257835 ·Status: RECRUITING
-
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT03664960 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
NCT03679676 ·Status: COMPLETED ·Phase: PHASE2
-
The Metabolomics of Anaphylaxis to Immunotherapy
NCT01666288 ·Status: WITHDRAWN
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935 ·Status: COMPLETED ·Phase: PHASE3
-
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis
NCT02775045 ·Status: COMPLETED
-
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
NCT02023151 ·Status: COMPLETED ·Phase: PHASE4
-
Sirolimus for Eosinophil-Associated Gastrointestinal Disorders
NCT01814059 ·Status: TERMINATED ·Phase: PHASE1
-
Omalizumab to Treat Eosinophilic Gastroenteritis
NCT00084097 ·Status: COMPLETED ·Phase: PHASE2
-
Eosinophilia Diagnosis
NCT02581514 ·Status: UNKNOWN ·Phase: NA
-
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
NCT03496571 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
NCT05084963 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
NCT00657891 ·Status: COMPLETED ·Phase: PHASE4
-
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
NCT03111628 ·Status: COMPLETED ·Phase: PHASE4
-
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
NCT01510626 ·Status: COMPLETED ·Phase: PHASE1
-
Dupilumab in Eosinophilic Gastritis
NCT03678545 ·Status: COMPLETED ·Phase: PHASE2
-
Monitoring Chronic Urticaria Basophil Irritability by Cytometry
NCT02671006 ·Status: COMPLETED